A detailed history of Sg Americas Securities, LLC transactions in Nuvation Bio Inc. stock. As of the latest transaction made, Sg Americas Securities, LLC holds 72,057 shares of NUVB stock, worth $203,200. This represents 0.0% of its overall portfolio holdings.

Number of Shares
72,057
Previous 31,916 125.77%
Holding current value
$203,200
Previous $93,000 77.42%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 03, 2024

BUY
$2.3 - $3.83 $92,324 - $153,740
40,141 Added 125.77%
72,057 $165,000
Q2 2024

Jul 12, 2024

SELL
$2.58 - $3.69 $48,271 - $69,039
-18,710 Reduced 36.96%
31,916 $93,000
Q1 2024

May 06, 2024

SELL
$1.46 - $3.97 $42,307 - $115,042
-28,978 Reduced 36.4%
50,626 $184,000
Q4 2023

Jan 12, 2024

SELL
$0.96 - $1.53 $29,397 - $46,851
-30,622 Reduced 27.78%
79,604 $120,000
Q3 2023

Oct 13, 2023

BUY
$1.26 - $2.1 $125,286 - $208,811
99,434 Added 921.37%
110,226 $148,000
Q2 2023

Jul 10, 2023

SELL
$1.56 - $1.84 $22,654 - $26,720
-14,522 Reduced 57.37%
10,792 $19,000
Q1 2023

Apr 28, 2023

BUY
$1.6 - $2.48 $7,756 - $12,023
4,848 Added 23.69%
25,314 $42,000
Q4 2022

Feb 02, 2023

SELL
$1.68 - $2.5 $340,309 - $506,412
-202,565 Reduced 90.82%
20,466 $39,000
Q3 2022

Oct 31, 2022

BUY
$0.29 - $4.04 $18,371 - $255,938
63,351 Added 39.67%
223,031 $500,000
Q2 2022

Jul 29, 2022

SELL
$3.24 - $5.85 $767,095 - $1.39 Million
-236,758 Reduced 59.72%
159,680 $517,000
Q1 2022

Apr 29, 2022

SELL
$4.6 - $8.83 $655,104 - $1.26 Million
-142,414 Reduced 26.43%
396,438 $2.09 Million
Q4 2021

Feb 07, 2022

BUY
$7.75 - $10.05 $3.95 Million - $5.12 Million
509,929 Added 1763.06%
538,852 $4.58 Million
Q3 2021

Nov 01, 2021

BUY
$7.78 - $10.0 $225,020 - $289,230
28,923 New
28,923 $287,000

Others Institutions Holding NUVB

About Nuvation Bio Inc.


  • Ticker NUVB
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 217,244,000
  • Market Cap $613M
  • Description
  • Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-422, a small molecule inhibitor targeting cyclin-dependent kinase (CDK)2, CDK4, and CDK6. It is also developing NUV-868, a selective oral small molecule BET inhibitor that e...
More about NUVB
Track This Portfolio

Track Sg Americas Securities, LLC Portfolio

Follow Sg Americas Securities, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Sg Americas Securities, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Sg Americas Securities, LLC with notifications on news.